# ANALYSIS OF EXCRETORY-SECRETORY ANTIGEN OF Entamoeba histolytica FOR DETECTION OF AMOEBIC LIVER ABSCESS

WONG WENG KIN

**NOVEMBER 2011** 

# ANALYSIS OF EXCRETORY-SECRETORY ANTIGEN OF Entamoeba histolytica FOR DETECTION OF AMOEBIC LIVER ABSCESS

BY

# WONG WENG KIN

# Thesis submitted in fulfillment of the requirements

for the degree of

**Master of Science** 

**NOVEMBER 2011** 

#### ACKNOWLEDGEMENT

First of all, I would like to thank God for the blessings that He gave to me during my postgraduate study. Throughout this study, I learned a lot of skills and gained many precious experiences. However, personally, the most important thing that I had earned was the process of overcoming uncertainties in life. 'Able to work in a group' and 'have strong determination' in whatever we decided were the two key points that needed to withstand these uncertainties.

Next, my special thanks go to my supervisor, Prof. Rahmah Noordin, and my co-supervisor, Dr. Lim Boon Huat. With their expertise and experiences in this research area, their guidance and advice really assisted me in problem solving and enforced my research progress. Besides, I also would like to extent my gratitude to Dr Zeehaida Mohamed and Dr. Alfonso Olivos Garcia for providing me with the serum samples and live *E. histolytica* parasite to start this project.

My special thanks also owe to officers and technologists from INFORMM, Medical Microbiology and Parasitology Department, HUSM and School of Health Sciences. I need to thank them for their assistance in serum collection, technical advice and guidance when I carried out my research. I would like to extend my gratitude to my friends from INFORMM, School of Health Sciences, and Medical Microbiology and Parasitology Department, HUSM. Without their co-operation, supports, helps, idea sharing and moral support, I may not be able to complete my study. I am grateful for the financial support from USM Fellowship, Postgraduate Research Grant Scheme (1001/INFORMM/8032030) from Institute of Postgraduate Studies, Fundamental Research Grant Scheme (203/CIPPM/6711122) and Research University Grant Scheme (1001/PPSK/813009).

Last but not least, I would like to extend my appreciation to my family and wife that continuously gave me moral support. Their patience, understanding and love were the most important source of inspiration that kept me focus on my study.

# TABLE OF CONTENTS

ACKNOWLEDGEMENT	II
TABLE OF CONTENTS	IV
LIST OF TABLES	X
LIST OF FIGURES	XI
LIST OF ABBREVIATIONS AND SYMBOLS	XIII
ABSTRAK	XIV
ABSTRACT	XVI

CHAPTE	R ONE	1
INTRODU	UCTION	1
1.1 GEN	ERAL	1
1.2 Enta	moeba histolytica	2
1.2.1	Transmission	6
1.2.2	Clinical Manifestations and Pathogenesis	7
1.2.3	Host Parasite Interaction	
1.2.4	Serological Immune Response of Amoebiasis in Human	
1.2.5	Other Amoebas	11
1.3 CLIN	VICAL DIAGNOSIS OF AMOEBIASIS	
1.3.1	Asymptomatic Carrier	12
1.3.2	Intestinal Amoebiasis	15
1.3.3	Extraintestinal Amoebiasis	17
1.4 TRE	ATMENT FOR AMOEBIASIS	17
1.5 LAB	ORATORY DIAGNOSIS OF AMOEBIASIS	
1.5.1	Microscopy	
1.5.2	Biochemical Method: Culture and Isoenzyme Analysis	
1.5.3	Antibody Detection	24
1.5.4	Antigen Detection	
1.5.5	DNA-Based Detection	
1.5.6	Point-of-Care Diagnostic Test	
1.6 AMC	DEBIASIS IN MALAYSIA	
1.7 STA	TEMENT OF PROBLEM AND RATIONALE OF STUDY	
1.8 AIM	S AND OBJECTIVES	

R TWO		. 37
LS AND METHO	ODS	. 37
DY DESIGN		37
ERIALS		39
Entamoeba histoly	vtica	39
Syrian Golden Har	mster	. 39
Chemicals and Re	agents	. 39
Kits and Consuma	bles	. 39
Equipments		. 39
HODS		. 40
Axenic Culture of	E. histolytica Trophozoites	. 40
(a) Preparation of	Buffers, Solutions and Culture medium	. 40
2.3.1 (ai) Try TY	pticase-Yeast Extract-Iron and Serum Medium, I-S-33	40
2.3.1 (aii) Hea	at-Inactivated Bovine Serum	41
2.3.1 (aiii) Ant	ibiotic Mixture	. 41
2.3.1 (aiv) Pho	sphate Buffer, 0.15 M	. 41
2.3.1 (av) PBS	S for Amoeba, PBS(A)	. 41
(b) Maintenance of	of <i>E. histolytica</i> Culture	. 42
(c) Mass Culture	of <i>E. histolytica</i>	. 42
(d) Cell Harvestin	ıg	. 43
(e) Cell Counting		. 44
Growth Profile Stu	ady of <i>E. histolytica</i> Trophozoites	. 46
Experimentally In	duced ALA in Hamster	. 46
Preparation of CS.	Α	. 51
(a) CSA		. 51
(b) Iodoacetamide	e, 0.5 M	. 51
(c) Preparation c EDTA	of Roche Complete Lysis-M buffer, Without	51
Protein Concentrat	tion Estimation by Bradford Protein Assay	. 52
Viability Study of Free Media	<i>E. histolytica</i> Trophozoites in Different Protein-	52
(a) Preliminary ( Protein-Free N	Observation of E. histolytica Morphology inMedia over Time	54
(b) Quantitative Viabilities in I	Data Analysis of <i>E. histolytica</i> Trophozoites Different Protein-Free Media	54
(c) Statistical Ana	ılysis	. 55
	<b>R TWO ALS AND METHO DY DESIGN ERIALS Entamoeba histoly</b> Syrian Golden Har         Chemicals and Re         Kits and Consuma         Equipments         HODS         Axenic Culture of         (a) Preparation of         2.3.1 (aii)         Protein Counting         Growth Profile Str         Call Counting         Growth Profile Str         Experimentally In         Preparation of CSJ         (a) CSA         (b) Iodoacetamide         (c) Preparation of CSJ         (a) CSA         Protein Concentration         Viability Study of         Free Media         (a) Preliminary Of         (b) Quantitative         (c) Statistical Ana	<b>R TWO MLS AND METHODS DY</b> DESIGN <b>ERIALS</b> <i>Entamoeba histolytica</i> Syrian Golden Hamster         Chemicals and Reagents       Kits and Consumables         Equipments       Equipments         HODS       Axenic Culture of <i>E. histolytica</i> Trophozoites         (a) Preparation of Buffers, Solutions and Culture medium       23.1 (aii)         Trypticase-Yeast Extract-Iron and Serum Medium, TYI-S-33.       2.3.1 (aiii)         2.3.1 (aii)       Heat-Inactivated Bovine Serum.         2.3.1 (aii)       Heat-Inactivated Bovine Serum.         2.3.1 (aii)       Hatibiotic Mixture         2.3.1 (aii)       Phosphate Buffer, 0.15 M.         2.3.1 (aii)       Phosphate Buffer, 0.15 M.         2.3.1 (av)       PBS for Amoeba, PBS(A)         (b) Maintenance of <i>E. histolytica</i> Culture       (c)         (c) Cell Counting.       Growth Profile Study of <i>E. histolytica</i> Trophozoites         Experimentally Induced ALA in Hamster       Preparation of CSA.         (a) CSA       (b) Iodoacetamide, 0.5 M.         (c) Preparation of Roche Complete Lysis-M buffer, Without EDTA.         Protein Concentration Estimation by Bradford Protein Assay.         Viability Study of <i>E. histolytica</i> Trophozoites in Different Protein-Free Media         (a) Preliminary Observation of <i>E. </i>

2.3.6	6 (d) Preparati	on of Protein-Free Defined Media	55
	2.3.6 (di)	PBS(A)-C&A	55
	2.3.6 (dii)	HBSS	55
	2.3.6 (diii)	Potassium Chloride, 3M	56
	2.3.6 (div)	Calcium Chloride, 100 mM	56
	2.3.6 (dv)	Magnesium Chloride, 100 mM	56
	2.3.6 (dvi)	Magnesium Sulfate, 100 mM	56
	2.3.6 (dvii)	Sodium Phosphate Dibasic, 100 mM	56
	2.3.6 (dviii)	Potassium Phosphate Monobasic, 100 mM	56
	2.3.6 (dix)	HBSS-C&A	57
	2.3.6 (dx)	DMEM	57
	2.3.6 (dxi)	DMEM-C&A	57
	2.3.6 (dxii)	RPMI 1640	57
	2.3.6 (dxiii)	RPMI-C&A	58
2.3.7	Optimization	of Cell Density of E. histolytica in DMEM-C&A	58
2.3.8	Preparation of	of E. histolytica Trophozoites ESA	59
2.3.8	8 (a) Collection	on of ESA	59
2.3.8	8 (b) Concentr	ration ESA via U-Tube Concentrator	59
2.3.8	8 (c) Investiga	tion of ESA Protein Profile over the 6-hour Incubatio	n
• • •	in Protein	n-Free Medium	60
2.3.9	SDS-PAGE	Analysis of CSA and ESA	61
2.3.9	P(a) Preparati	on of Buffers and Reagents for SDS-PAGE	62
	2.3.9 (a1)	SDS-PAGE Stacking Buffer	62
	2.3.9 (a11)	SDS-PAGE Resolving Buffer	62
	2.3.9 (a111)	Ammonium Persulfate, APS, 10 %	62
	2.3.9 (aiv)	Sodium Dodecyl Sulfate, SDS, 10 %	62
	2.3.9 (av)	Sample Buffer, 2X	64
	2.3.9 (av1)	60 mM Tris HCl pH 6.8	64
	2.3.9 (avii)	Electrode Buffer, 10X	64
2.3.10	Regular Cool	massie Brilliant Blue (CBB) R250 Stain	64
2.3.1	10 (a) Preparati	ion of Reagents for CBB Stain	65
	2.3.10 (a1)	CBB Staining Solution	65
	2.3.10 (a11)	Destainer	65
2.3.11	RAMA Stain	1	65
2.3.1	11 (a) Preparati	ion of Reagents for RAMA Stain	66
	2.3.11 (ai)	CBB 250/Methanol Stain, 4X	66
	2.3.11 (aii)	30 % Ammonium Sulfate, 10X	66

	2.3.11 (aiii)	RAMA Stain Working Solution	66
2.3.12	Silver Stain		66
2.3.1	2 (a) Preparation	on of Reagents for Silver Stain	67
	2.3.12 (ai)	3.12 (ai) Fixing Solution	
	2.3.12 (aii)	Incubation Solution	67
	2.3.12 (aiii)	Staining Solution	67
	2.3.12 (aiv)	Developing Solution	67
	2.3.12 (av)	Stop Solution	67
2.3.13	Western Blot	Analysis of the ESA	68
2.3.1	3 (a) Western	Blot	68
2.3.1	3 (b) Optimiza	tion of Western Blot Parameters	69
	2.3.13 (bi)	Optimization of Antigen Mass Loaded in SDS- PAGE	69
	2.3.13 (bii)	Optimization of Protein Amount Loaded and Primary Antibody Dilutions in Western Blot Analysis	70
	2.3.13 (biii)	Optimization of Secondary Antibody for Western Blot Analysis	70
	2.3.13 (biv)	Optimization of Blocking Reagent for Western Blot Analysis	70
2.3.1	3 (c) Preparation	on of Buffers and Reagents for Western Blot Analysis	71
	2.3.13 (ci)	Towbin Transfer Buffer	71
	2.3.13 (cii)	Ponceau-S Staining Solution, 0.5 %	71
	2.3.13 (ciii)	Amido Black	72
	2.3.13 (civ)	Tris Buffered Saline, 10X	72
	2.3.13 (cv)	TBS-Tween 20, 0.1 % (TBS-T)	72
	2.3.13 (cvi)	Roche Blocking Solution	72
2.3.14	Determination	n of Sensitivity and Specificity of Antigenic Proteins	73
2.3.1	4 (a) Determin	ation of Sensitivity	73
2.3.1	4 (b) Determin	ation of Specificity	73
2.3.15	Protein Fracti	onation via Agilent 3100 OFFGEL Fractionator	74
2.3.1	5 (a) Preparation	on of Buffers and Reagents for Protein Fractionation	75
	2.3.15 (ai)	Protein OFFGEL Stock Solution, 1.25X	75
	2.3.15 (aii)	IPG Strip Rehydration Buffer	75
	2.3.15 (aiii)	IPG Strip Sample Buffer	76
	2.3.15 (aiv)	Sample Buffer, 5X	76
2.3.16	Proteins Iden	tification via Mass Spectrometry	76
2.3.17	Collection of	Serum Samples	76

СНА	PTE	R THREE	. 83
RES	ULT.		. 83
3.1	GRO	WTH PROFILES OF E. histolytica TROPHOZOITES	. 83
3.2	COM EFFE SUPE TRO	IPARISION OF PROTEIN-FREE DEFINED MEDIA AND ECT OF L-CYSTEINE AND ASCORBIC ACID PLEMENTATION ON VIABILITY OF <i>E. histolytica</i> PHOZOITES	. 85
3.2	2.1	Morphology of <i>E. histolytica</i> after Prolonged Incubation in Protein- Free Media	. 85
3.2	2.2	Viability of <i>E. histolytica</i> in Different Protein-Free Medium over Time	. 85
3.3	OPTI	MUM CELL DENSITY OF E. histolytica IN DMEM-C&A	. 91
3.4	PRO' DIFF	TEIN AND ANTIGENIC PROTEIN PROFILES OF ESA IN ERENT PROTEIN-FREE MEDIA	. 91
3.5	ESA INCU	EXPRESSION PROFILE OVER THE TIME DURATION POST JBATED IN PROTEIN-FREE MEDIUM	. 94
3.6	OPTI	MIZATION OF ESA WESTERN BLOT PROFILE (SMALL GEL)	. 96
3.7	DEM PRO	IONSTRATION OF THE DIFFERENCES OF PROTEIN FILES BETWEEN CSA AND ESA	. 96
3.	7.1	SDS-PAGE	. 98
3.	7.2	Western Blot	. 98
3.8	OPTI FOR	MIZATION OF WESTERN BLOT PARAMETERS (BIG GEL) SCREENING OF ESA WITH INDIVIDUAL SERUM SAMPLES	101
3.9	ANT HUM	IBODY SCREENING OF ESA WITH DIFFERENT INDIVIDUAL IAN SERUM SAMPLES	106
3.10	DET	ERMINATION OF SENSITIVITY AND SPECIFICITY	111
3.11	WES POSI	TERN BLOT ANALYSIS OF ESA WITH HAMSTER ALA TIVE SERUM SAMPLES	111
3.12	ANA	LYSIS OF ESA WITH 2D-SDS-PAGE AND WESTERN BLOT	117
3.	12.1	Fractionation of ESA via Agilent 31000 FFGEL Fractionator	117
3.	12.2	Western Blot Analysis of Fractionated ESA	117
3.13	MAS PRO	S-SPECTROMETRY ANALYSIS OF TARGETED ANTIGENIC	118
3.	13.1	Result of MALDI-TOF-TOF Analysis for 110 kDa ESA	118
3.	13.2	Result of MALDI-TOF-TOF Analysis for 152 kDa ESA	124
3.	13.3	Result of MALDI-TOF-TOF Analysis for 131 kDa ESA	124
СНА	PTEI	R FOUR	127
DISC	CUSSI	ION	127

4.2	AXE	NIC GROWTH OF E. histolytica	. 129
4.3	OPT	IMIZATION OF METHOD FOR ESA COLLECTION	. 130
4.	3.1	E. histolytica Culture	. 130
4.	3.2	Maintenance <i>E. histolytica</i> Viability in Protein-Free Media for Extended Duration	. 131
4.	3.3	Collection of ESA	. 134
4.4	SDS- HUM	PAGE AND WESTERN BLOT ANALYSIS OF ESA USING IAN AND HAMSTER SERA	. 136
4.5	MAI PRO	DI-TOF-TOF ANALYSIS OF THE TARGETED ANTIGENIC	. 141
REF	EREN	NCES	. 143

# APPENDICES

APPENDIX	A: LIST OF CHEMICALS AND REAGENTS
APPENDIX	B: LIST OF KITS AND CONSUMABLES
APPENDIX	C: LIST OF EQUIPMENTS
APPENDIX	D: PUBLISHED MANUSCRIPTS
APPENDIX	E: PRESENTATIONS
APPENDIX	H: HUMAN ETHICAL APPROVAL
APPENDIX	I: ANIMAL ETHICAL APPROVAL

# LIST OF TABLES

I	Page
ble 1.1 Classification of amoebiasis	9
ble 1.2 Morphologic features and pathogenicity of intestinal amoeba (Tanyuksel and Petri, 2003)	13
ble 1.3 Drugs treatment for amoebiasis (The-Medical-Letter, 2010)	19
ble 1.4 Mechanism and adverse effect of treatment drug for amoebiasis (Stanley, 2003)	20
ble 1.5 Commercially available antibody detection assays for diagnosis of amoebiasis	26
ble 1.6 Commercially available antigen detection assays for diagnosis of amoebiasis	29
ble 2.1 Preparation of BSA protein standards for Bradford protein assay	53
ble 2.2 Gel mixtures for SDS-PAGE	63
ble 2.3 Data of the 24 human ALA positive serum samples	78
ble 2.4 Data of the 14 human ALA positive serum samples with Real- time PCR confirmation	81
ble 2.5 Data of the 33 human serum samples from other infections	82
ble 3.1 Kruskal-Wallis test analysis of difference between percentage viability medians among the test media	88
ble 3.2 Post hoc analysis of the difference in trophozoite viabilities in various culture media	89
ble 3.3 Frequency distribution of each targeted antigenic bands when ESA was probed with human ALA positive serum samples	. 113
ble 3.4 Sensitivity and specificity of each targeted antigenic bands of ESA	. 114

## LIST OF FIGURES

	Pa	age
Figure 1.1	Life cycle of <i>E. histolytica</i> (CDC, 2010)	4
Figure 1.2	Morphological descriptions of <i>E. histolytica</i> trophozoite and cyst (CDC, 2010)	5
Figure 1.3	Amoebas found in stool specimens of humans (Baron, 1996)	14
Figure 1.4	Classical flow chart for diagnosis of amoebiasis	16
Figure 2.1	Flow chart of the study methodology	38
Figure 2.2	Schematic diagrams of cells counting area in Neubauer's chamber	45
Figure 2.3	Images of the surgical procedure to experimentally induced ALA in hamster	47
Figure 2.4	Images of the of the isolation of <i>E. histolytica</i> trophozoites from ALA tissue of hamster	48
Figure 3.1	Growth patterns of <i>E. histolytica</i> trophozoites	84
Figure 3.2	Morphology of axenic <i>E. histolytica</i> trophozoites in PBS(A) at magnification of 200X during (a) log phase and (b) after incubation for 6 hours.	87
Figure 3.3	Percentage viability profiles of <i>E. histolytica</i> trophozoites in different protein-free media during 8-hour incubation period	90
Figure 3.4	Percentage viability profile of <i>E. histolytica</i> trophozoite in DMEM-C&A at 6 hour post incubation with different seeded cell densities	92
Figure 3.5	Protein profiles of ESA from different batches and the two media (RPMI-C&A and DMEM-C&A) preparations	93
Figure 3.6	Expression profile of ESA over time duration incubation in RPMI-C&A	95
Figure 3.7	Optimization of ESA Western blot profile with different protein amounts and serum dilutions	97
Figure 3.8	SDS-PAGE protein profiles of CSA and ESA	99
Figure 3.9	Western blot analyses of CSA and ESA with individual human ALA positive serum samples	00
Figure 3.10	Protein profile of ESA with different protein mass	02
Figure 3.11	Protein profile of ESA preparative gel	03

Figure 3.12	Comparison of different blocking conditions and antibody dilutions in Western blot analysis of ESA	104
Figure 3.13	Comparison of two dilutions of individual human serum samples in Western blot analysis of ESA	105
Figure 3.14	Western blot profile of ESA probed with individual human ALA positive serum samples confirmed by IHA, clinical manifestations, radiological imaging and Real-Time PCR of pus aspirate.	107
Figure 3.15	Western blot profile of ESA probed with individual human ALA positive serum confirmed with IHA, clinical manifestations and radiological imaging.	108
Figure 3.16	Western blot profile of ESA probed with individual human IHA negative serum samples	109
Figure 3.18	Antigen profile of ESA probed with hamster ALA positive serum samples	115
Figure 3.19	Antigen profile of ESA probed with human, hamster ALA and uninfected hamster serum samples	116
Figure 3.20	SDS-PAGE protein profiles of fractionated ESA	119
Figure 3.21	Antigen profiles of fractionated ESA probed with human and hamster pooled serum	120
Figure 3.22	Antigen profiles of selected ESA fractions probed with individual human and/or hamster serum samples	121
Figure 3.23	SDS-PAGE protein profile of selected ESA fraction where the targeted protein bands were excised and sent for MALDI-TOF-TOF analysis.	122
Figure 3.24	Result of MALDI-TOF-TOF for 110 kDa protein	123
Figure 3.25	Result of MALDI-TOF-TOF for 152 kDa protein	125
Figure 3.26	Result of MALDI-TOF-TOF for 130 kDa protein	126

# LIST OF ABBREVIATIONS AND SYMBOLS

<	Less than	kVh	Kilovolt per hour
%	Percentage	mW	Milliwatt
±	More or less	mA	Milliampere
×	Multiply by	V	Volt
$\geq$	More than or equal to	dH <sub>2</sub> O	Distilled water
°C	Degree Celsius	ECL	Enhanced
μg	Microgram		chemiluminescent
μL	Microliter	ESA	Excretory-secretory
μm	Micrometer		antigen
BSA	Bovine serum albumin	CBB	Coomassie brilliant blue
с.а.	circa - 'Approximately'	RAMA	CBB R250, Acetic acid,
cm	Centimeter		Methanol, Ammonium
CSA	Crude soluble antigen		sulphate
DNA	Deoxyribonucleic acid	HBSS	Hank's balanced salt
e.g.	exempli gratia - 'for example'		solution
et al	et alii - 'and others'	RPMI	Roswell Park Memorial
etc	et cetera - 'and so forth'		Institute medium, no
g	Gravity		1640
g	Gram	DMEM	Dulbecco's Modified
HRP	Horseradish peroxidase		Eagle Medium
i.e.	<i>id est</i> - 'that is'	SDS-	Sodium Dodecyl
Ig	Immunoglobulin	PAGE	Sulfate-Polyacrylamide
IPG	Immobilized pH gradient		Gel Electrophoresis
kDa	Kilodalton	TYI-S-33	Trypticase-Yeast
L	Liter		Extract-Iron and Serum
Μ	Molar	PBS(A)	Phosphate buffered
Mb	Megabase		saline for amoeba
mg	Milligram	C&A	0.1 % L-cysteine and
min	Minute		0.02 % ascorbic acid
mL	Milliliter	IHA	Indirect
mМ	Millimolar		Haemagglutination Assay
MW	Molecular weight standard	ELISA	Enzyme-Linked
NC	Nitrocellulose		Immunosorbent Assay
OD	Optical density		
PCR	Polymerase Chain Reaction		
PES	Polyethersulfone		
psi	Pound-force per square inch		
TMB	3,3',5,5'-Tetramethylbenzidine		

- *via* 'by means of' or 'by way of'
- X Times

β beta

# ANALISIS ANTIGEN EKSKRETORI-SEKRETORI DARIPADA Entamoeba histolytica UNTUK PENGESANAN ABSES HATI AMEBA

## ABSTRAK

Amebiasis ialah penyakit protozoa usus yang disebabkan oleh *Entamoeba histolytica*. Ia melibatkan 50 juta orang di seluruh dunia dan menyebabkan 100,000 kes kematian setiap tahun. Abses hati ameba (ALA) merupakan manifestasi klinikal yang paling lazim bagi amebiasis luar usus. Ia boleh menyebabkan kematian jika diagnosis dan rawatan terlewat. Sehingga sekarang, diagnosis untuk ALA masih bersandar kepada hasil keputusan sejarah klinikal, pengimejan radiologi, dan ujian diagnosis makmal. Ujian serologi tetap dijadikan pilihan kerana ia tidak invasif dan senang dijalankan. Namum, ujian serologi yang lazim digunakan, iaitu 'indirect haemagglutination assay' (IHA) dan 'TechLab *E. histolytica* II ELISA' menunjukkan sensitiviti yang rendah di kawasan endemik, disebabkan oleh latar belakang antibodi anti-ameba yang tinggi dalam populasi itu dan penerimaan rawatan terdahulu oleh pesakit. Oleh sebab itu, kajian ini bertujuan untuk menganalisis protein antigenik dalam antigen ekskretori-sekretori (ESA) *E. histolytica*, dan mengenalpasti satu penanda biologi yang berpontensi untuk menambah baik ujian serologi bagi ALA.

Satu larutan media tanpa protein yang mengandungi 0.1 % L-cysteine dan 0.02 % asid askorbik serta dapat memelihara  $\geq$  95 % trofozoit hidup bagi sekurangkurangnya 8 jam, iaitu DMEM-C&A atau RPMI-C&A telah dioptimum dan diguna untuk penyediaan ESA. Masa pengeraman trofozoit dalam larutan media itu telah dikurangkan kepada 6 jam bagi mengganti masa yang telah digunakan untuk

mengumpul kultur trofozoit berskala besar. Ketumpatan maksimum trofozoit dalam medium ialah  $0.8 \times 10^6$  sel per mL. Kemudian, ESA dikumpul melalui proses pemekatan dan penukaran larutan penampan sebelum digunakan dalam analisis. Dalam analisis Western blot ESA yang diuji dengan serum manusia berpenyakit ALA (n = 38), dua antigenik protein menunjuk sensitiviti melebihi 80 %, iaitu protein 152 kDa dan 110 kDa. Spesifisiti kedua-dua protein ini ialah 100 % kerana tiada reaksi ditunjukkan apabila ianya diuji dengan serum manusia yang normal (n = 30) dan jangkitan lain (n = 33), di mana IHAnya adalah negatif. Selain itu, analisis Western blot ESA yang diuji dengan serum daripada hamster berpenyakit ALA (n = 9) menunjukkan protein antigenik 130 kDa, 110 kDa dan 100 kDa juga bereaksi dengan antibodi manusia. Analisis lanjutan dengan 2D-Western blot menunjukkan nilai pI bagi ketiga-tiga protein antigenic ini masing-masing ialah 5.33-5.91, 5.91-6.5 dan 5.91-6.5. Keputusan daripada MALDI-TOF-TOF menunjukan protein 152 kDa ialah lektin *E. histolytica* yang telah dilaporkan sebelum ini dan 110 kDa ialah enzim piruvat fosfat dikinase E. histolytica. Protein 130 kDa tidak dapat dikenalpasti walaupun proses pemekatan protein telah dicuba, namun kandungannya dalam ESA sangat rendah. Kajian ini berjaya mengenalpasti satu protein daripada E. histolytica, iaitu 110 kDa protein yang berpotensi untuk digunakan dalam diagnosis ALA.

# ANALYSIS OF EXCRETORY-SECRETORY ANTIGEN OF Entamoeba histolytica FOR DETECTION OF AMOEBIC LIVER ABSCESS

## ABSTRACT

Amoebiasis is an enteric protozoan disease caused by *Entamoeba histolytica*. It affects 50 million people worldwide and causes up to 100,000 fatal cases annually. Amoebic liver abscess (ALA) is the most common clinical manifestation of extraintestinal amoebiasis. It can lead to fatal outcome if early diagnosis and treatment are not obtained. To date, diagnosis of ALA is dependent on clinical history, radiological imaging, and laboratory diagnosis. Serodiagnosis is widely used because it is non-invasive and easy to perform. However, the commonly used immuno-haemagglutination assay (IHA) and TechLab *E. histolytica* II ELISA showed low sensitivities in endemic areas due to the high anti-amoebic antibody background in the population and prior treatment of patients. Thus, the aims of this study were to analyse the antigenic proteins of excretory-secretory antigen (ESA) collected from *E. histolytica*, and to identify potential biomarker(s) which could improve the serodiagnosis of ALA.

A protein-free defined medium supplemented with 0.1 % L-cysteine and 0.02 % ascorbic acid which could sustain the  $\geq$  95 % viability of the anaerobic trophozoite for at least 8 hours *i.e.* DMEM-C&A or RMPI-C&A was optimized and the latter used for ESA preparation. The incubation period of trophozoites in the medium was reduced to 6 hours, in order to compensate the time used for harvesting the mass cultured trophozoites. The maximum trophozoites density in the medium was 0.8 x  $10^6$  cells per mL. ESA was then collected, concentrated and buffer-exchanged prior to use. Western blot analysis of ESA probed with human serum samples with ALA (n = 38) revealed two antigenic proteins with sensitivities above 80 %, *i.e.* 152 kDa and 110 kDa. Their specificities were 100 % as they were not recognised by normal human serum samples (n = 30) and other infections (n = 33) which were IHA negative. On the other hand, Western blot analysis of ESA probed with hamster serum samples with ALA (n = 9) revealed 130 kDa, 110 kDa and 100 kDa antigenic proteins which were also seen with human sera. Further 2D-Western blot analysis revealed that the pI values of these three antigenic proteins were 5.33-5.91, 5.91-6.5 and 5.91-6.5, respectively. In the MALDI-TOF-TOF analysis, 152 kDa protein was identified as the *E. histolytica* lectin which has been previously reported, 110 kDa as *E. histolytica* pyruvate phosphate dikinase, while 130 kDa protein could not be identified due to its low amount in ESA despite efforts at concentrating it. Thus, this study has successfully identified that 110 kDa *E. histolytica* protein is potentially useful for diagnosis of ALA.

#### **CHAPTER ONE**

#### **INTRODUCTION**

#### 1.1 GENERAL

Amoebiasis is an enteric protozoan disease caused by *Entamoeba histolytica* (WHO, 1997). It is a cosmopolitan parasitic disease which affects 40-50 million individuals of the world population and causes up to 100,000 of fatal cases annually (Walsh, 1986). It is the third common cause of death due to parasitic disease after malaria and schistosomiasis. It commonly occurs at places with poor sanitation and low socio-economic conditions. The prevalence rate is higher in tropical and sub-tropical countries such as India, Mexico, and in South East Asia (Widmer and Nettleman, 1991).

The high risk groups for amoebiasis include travelers, male homosexuals and those with poor personal hygiene practice (Lazara Rojas Rivero *et al.*, 2008). The transmission is worldwide due to the ease of world travel (Nari *et al.*, 2008). Faecal oral route is responsible for the transmission through the ingestion of the infective stage cysts. On the other hand, human to human transmission through oral-genital or oral-anal contact also have been reported among homosexuals (Hung, 2007). Among 10 % of the infected humans, only 10 % develops the clinical symptoms; while in the remainder the infection persists as asymptomatic carriers. Among the 10 % symptomatic patients, 90 % may present as intestinal amoebiasis and 10 % may develop into amoebic liver abscess (ALA). ALA is the most common clinical

manifestation of extraintestinal amoebiasis and potentially fatal if early diagnosis and treatment is not sought (Zlobl, 2001).

According to a World Health Organization (WHO) report, the elementary means for eradicating of amoebiasis is basically based on the improvement of the quality of living conditions (*e.g.* clean water and food) and education (*e.g.* hand washing and personal hygiene) in the countries where amoebiasis is prevalent (Salles *et al.*, 2003). This strategy was evidenced by the success of Cuba in eliminating malaria, schistosomiasis, leishmaniasis and Chagas by improving socioeconomic conditions, health, sanitation and water supply (Lazara Rojas Rivero *et al.*, 2008). Similar to Malaysia, the statistics of parasitic disease had shown positive outcomes as the number of cases declined over the years after the implementation of socioeconomic development in the country. Nevertheless, the number of parasitic infections is relatively high in Malaysia as compared to the developed countries. For example, the prevalence of water-borne diseases among the aborigines, 'Orang Asli' is still high (Yusof and Ghani, 2009; Ministry-of-Health-Malaysia, 2006; Mak, 2004). Therefore, continuous improvement of health program and monitoring of parasitic diseases are still needed.

## 1.2 Entamoeba histolytica

The trophozoite form of *E. histolytica* was described by Lösch in 1875 from a case of patient with chronic dysentery, whereby, Quincke and Roos later described its cyst form in 1893 (Marshall *et al.*, 1997). The name *Entamoeba histolytica* for dysentery producing amoeba was named by Schaudinn in 1903. In 1925, Brumpt reported the presence of *E. histolytica*-like non-pathogenic strain *E. dispar* (Ackers, 2002;

Jackson, 1998; Brumpt, 1928). According to taxonomy classification, *E. histolytica* belongs to the kingdom protista, subkingdom protozoa, phylum sarcomastigophora, subphylum sarcodina, class lobosea, order amoebida, family endamoebidae, genus *Entamoeba* and species *E. histolytica*. It is a unicellular eukaryotic organism, containing nucleus and multiply through binary fission. It is also a heterotrophic and pleomorphic organism, in which it needs nutrient supplies from the environment and performs locomotion through pseudopodia movement. It is an endoparasite as it stays inside a host and preys for food like bacteria, red blood cells or food particles in host through formation of pseudopodia. Based on electrophoretic karyotyping *via* pulse gel electrophoresis, it was predicted that this parasite contains 14 chromosomes and with the genome size of *c.a.* 24 Mb (Loftus *et al.*, 2005; Stanley, 2003; Baron, 1996).

The life cycle of *E. histolytica* consisted of cyst and trophozoite, as shown in Figures 1.1 and 1.2. Upon entering into human digestive track, the cyst passes through the stomach and excysts at the distal end of ileum or colon where the quadrinucleate cyst is activated by the intestinal secretions and develops into four motile metacysts or metacystic trophozoites. Next, the motile trophozoites are formed and multiply *via* binary fission in the intestine. Under adverse condition, some of the trophozoites may undergo encystment. During encystment, the nucleus undergoes two division processes to produce a quadrinucleate cyst and may be excreted from the body in stool. The subsequent host may get infected when they ingest food or drink, contaminated with the cyst. Thus far, human and some none human primates are the only reported natural hosts (Rivera *et al.*, 2010; Hankenson *et al.*, 2003; Stanley, 2003).



Figure 1.1 Life cycle of *E. histolytica* (CDC, 2010)



Image source: http://www.dpd.cdc.gov/dpdx/html/imagelibrary/Amebiasis il.htm

# A: Erythrophagocyted trophozoites of *E. histolytica/E. dispar*

(Trichrome stained: Erythrocytes appear as dark inclusion bodies. The nuclei with centrally located karyosome and lined by thin layer of uniform peripheral chromatin were stained in blue purple color.)

#### B: Cyst of E. histolytica/E. dispar

(Trichrome stained: Three nuclei and a bluntend chromatoid body were well demonstrated.)



Figure 1.2 Morphological descriptions of *E. histolytica* trophozoite and cyst (CDC, 2010)

The cyst is the infective dormant stage and resistant to environmental stresses (*e.g.* oxygen, gastric acid). It is round in shape, 10-20  $\mu$ m in diameter, and enclosed by a retractile wall. A mature cyst contains four nuclei. Each nucleus consists of a central karyosome surrounded by peripheral chromatin. Rod-like chromatoid bodies made of the assemblies of glycogen and ribosome may also be present, but they are more common in immature cysts. On the other hand, the trophozoite of *E. histolytica* is actively multiplying and highly motile in human host. Its size is generally 10-60  $\mu$ m and pleomorphic in shape. It is an anaerobic organism and does not possess mitochondria. The main energy source of trophozoites is acquired from the anaerobic conversion of glucose and pyruvate to ethanol. Red blood cells and/or bacteria are sometimes found in the endoplasm. Under permanent trichrome stain, the nucleus contains a distinctive central karyosome and surrounded by a delicate distinct membrane with beaded chromatin (Lohia, 2003).

#### 1.2.1 Transmission

Generally, *E. histolytica* is transmitted *via* faecal oral route through the ingestion of food and/or water contaminated with cysts, which could come from food handlers, house flies, cockroaches, and the use of human excreta as fertilizers for growing vegetables and fruits (Hankenson *et al.*, 2003). Amoebiasis could also be transmitted among homosexuals *via* oral-genital or oral-anal contact. The life span of trophozoites in stool is rather short. However, the cysts are more robust, resistant to environmental pressure, and able to survive in stool for up to about 12 days. High incidence of amoebiasis occurs among those between 26 - 30 years old as compared to children below 5 years old. The incidents of ALA are higher in males than females with a ratio of 10:1 or higher (Lee *et al.*, 2009; Akgun *et al.*, 1999).

### 1.2.2 Clinical Manifestations and Pathogenesis

The pathogenesis of amoebiasis is highly dependent on the virulence of trophozoites and host-parasite interaction. The clinical presentations of the individual infected by *E. histolytica* are wide as shown in Table 1.1. The trophozoites may just reside in the infected individual as commensally organism without tissue invasion. If mucosal invasion occurs, the clinical manifestation may vary from local mucosal erosion to mucosal ulceration depending on depth of the invasion. Mucosal erosion may lead to diarrhoea and the severity increased with the area of the affected colon. If the lesions are toward the distal part of the colon, it is more likely the individual will have the symptoms of intestinal amoebiasis, instead of asymptomatic local caecal lesion. When the rectal bleeding occurs, the blood in the faecal specimen may be occult, which is demonstrable only by chemical testing. The individual may also experience abdominal tenderness or cramping pain.

The invasion of trophozoites often started at the intestinal compartment and progress to extraintestinal if the trophozoites break into the blood stream. In the benign phase of intestinal amoebiasis, the individual will experience mild to severe diarrhoea, which is also classified as non-dysenteric colitis. However, when the area and depth of lesion increase, diarrhoea will be replaced by dysenteric stools, which consist largely of mucous and blood without faeces. The affected individual may experience fever, dehydration, and electrolytes imbalance. Occasionally, but less frequently, local invasion of trophozoites will evoke a proliferative granulomatous response at the ulcerative site and turn into pseudo-tumor, known as amoeboma. Extraintestinal amoebiasis is results from the haematogenous spread of trophozoites to liver, lung, brain or skin. ALA is the most common clinical manifestation which is due to the metastasis of trophozoites to liver through the portal vein. A focal amoebic abscess in the liver would be sufficient to represent the metastasis of trophozoites from intestine to liver. Intestinal amoebiasis symptoms need not be present simultaneously. The size of the abscess may grow bigger with the enlargement of the liver mass in a symptomatic patient. The individual may experience right upper quadrant pain, tenderness of the liver, fever, jaundice and nausea. Fatality may occur if early diagnosis and treatment are not sought.

#### **1.2.3 Host Parasite Interaction**

The actual mechanism of host defence against *E. histolytica* remains unclear. Both innate and acquired immunity are reported to be important for prevention of amoebiasis. The first defence of amoebiasis in human is the mucosal layer of intestine, which serves to prevent contact between trophozoites and intestinal epithelial cells. Passive immunity is also contributed by the natural flora present in human intestine. They compete with the trophozoites to adhere to host colonic cells. Often, cell mediated immunity is polarized toward Th1 immune response, in which they limit the extent of invasive amoebiasis and protect the host from recurrent infection following recovery from the disease (Supali *et al.*, 2010; Solaymani-Mohammadi and Petri, 2008).

Table 1.1Classification of amoebiasis

WHO Clinical Classification of		Pathophysiologic Mechanism		
Amoe	biasis Infection			
Asymptomatic infection		Colonization without tissue invasion		
Symptomatic infection		Invasive infection		
Int	estinal amoebiasis			
A.	Amoebic dysentery	Fulminant ulcerative intestinal disease		
B.	Nondysenteric gastroenteritis	Ulcerative intestinal disease		
C.	Amoeboma	Proliferative intestinal disease		
D.	Complicated intestinal amoebiasis	Perforation, haemorrhage, fistula		
E.	Post-amoebic colitis	Mechanism unknown		
Ext	traintestinal amoebiasis			
A.	Nonspecific hepatomegaly	Intestinal infection with no demonstrable invasion		
B.	Acute nonspecific infection	Amoebas in liver but without abscess		
C.	Amoebic abscess	Focal structural lesion		
D.	Amoebic abscess	Direct extension to pleura, lung,		
	complicated	peritoneum, or pericardium		
E.	Amoebic cutis	Direct extension to skin		
F.	Visceral amoebiasis	Metastatic infection of lung, spleen, or		
		brain		

On the other hand, the resistance of trophozoites and its virulence factors are the key factors for disease development and progression. The virulence factors of E. histolytica included Gal/GalNAc lectin, proteases, and amoebapores. Gal/GalNAc lectin is a surface membrane protein that assists the adherence of trophozoites to the host cell via high affinity binding to the O-linked protein, galactose (Gal) and Nacetyl-D-galactosamine (NAcGal) present in the mucosal layer of intestine. This lectin has been shown to contribute to lysis of host cells through contact-dependent killing via apoptosis. Following adherence of trophozoites onto the mucosal surface, it secretes proteases that contribute to the erosion of intestinal mucus by disruption of mucin 2 (MUC2) polymerization. These proteases are able to rapidly degrade the mucosal IgA and serum IgG (Garcia-Nieto et al., 2008; Garcia-Zepeda et al., 2007; Tarleton and Petri, 2004; Tran et al., 1998). The trophozoites also secrete an amoebapore, a pore-forming protein which lysed host cells. Besides, the lysed cells like neutrophils and granulocytes also release toxic products that further increase host cell tissue destruction (Leippe and Herbst, 2004). A recent study showed that the trophozoites expressed CD59-like protein on its surface to protect itself against the cytolytic action of the membrane attack complex, by inhibiting the polymerization of the C9 protein, which is responsible for the modification of membrane phospholipid layer (Ventura-Juarez et al., 2009; Zambrano-Villa et al., 2002).

## 1.2.4 Serological Immune Response of Amoebiasis in Human

Immune responses of human with amoebiasis are complex due to the wide range of its clinical presentation. Upon the invasion of *E. histolytica*, the immune response of human is elicited within seven days (Kaur *et al.*, 2004). As a sign of mucosal invasion, IgA is secreted in the mucosal layer of intestine (Haque *et al.*, 2003). It has

been shown that high level of mucosal-IgA, saliva-IgA and serum-IgG may persist for at least one year after treatment. The levels of these antibodies are higher in patients with ALA as compared to amoebic dysentery cases. These persistent antibodies contribute to the background anti-amoebic antibodies among population in endemic areas. Besides, recurrent infection often occur (Haque and Petri, 2006; Valenzuela et al., 2001; Haque et al., 1997). Higher level of anti-lectin antibodies was reported in patients with amoebic dysentery and ALA, as compared to asymptomatic cysts passer. In ALA cases, high level of IgG1 (60 % of total antilectin IgG) was found to be present, which suggested Th2 immune response; while high level of IgG1 (40 % of total anti-lectin IgG) and IgG4 (30 % of total anti-lectin IgG) were found to be present in both patients with intestinal amoebiasis and asymptomatic cysts passer (Kaur et al., 2004). The level of IgM was higher in cases of intestinal amoebiasis, as compared to ALA and asymptomatic cyst passer. High level of anti-amoebic antibodies was reported in endemic areas, but recurrent infections still occur and unremitted in many patients. Therefore the protection roles of these antibodies against E. histolytica remain controversial (Tarleton and Petri, 2004; Trissl, 1982).

## 1.2.5 Other Amoebas

Besides the parasitic amoeba that requires host, there are free living species as well, *i.e. Naegleria* spp., *Acantamoeba* spp., *Balamuthia mandrillaris* and *Sappinia diploidea* (Schuster and Visvesvara, 2004; Schuster, 2002). Several species of these non-pathogenic amoebas are reported to be found in human body, *i.e. E. polecki, Iodamoeba butschlii, E. coli, E. moshkovskii, E. gingivalis, E. chattoni* and *Endolimax nana* (Zlobl, 2001). Table 1.2 shows the description of the features and

characteristics of the amoebas found in human intestine. Figure 1.3 shows the morphology of the amoebas that could be found in humans stool samples. Since the discovery of the morphologically identical but genetically different *E. dispar*, the result from microscopy is no longer specific for detection of *E. histolytica*. However erythrophagocyted trophozoites are suggested to highly correlate with the presence of *E. histolytica* and invasive disease. *E. dispar* had been classified by WHO as the non-pathogenic strain (WHO, 1997).

## 1.3 CLINICAL DIAGNOSIS OF AMOEBIASIS

The clinical diagnosis of individual infected with *E. histolytica* could be categorized into three groups based on their clinical manifestations, *i.e.* asymptomatic carrier, intestinal amoebiasis and extraintestinal amoebiasis.

### **1.3.1** Asymptomatic Carrier

Asymptomatic carriers are those with no signs and symptoms of either intestinal or extraintestinal amoebiasis, but with the presence of *E. histolytica* trophozoites or cysts in the intestine or stool. Majority of the affected people falls into this category. They are detected by microscopy examination of trophozoites and/or cysts in the stool. Since microscopy could not distinguish among species of pathogenic/non-pathogenic *Entamoeba*, the application of DNA-based or stool antigen detection test is highly recommended (Baron, 1996).

Characteristics	<i>E. histolytica, E. dispar</i> and <i>E. moshkovskii</i> <sup>a</sup>	E. hartmanni	E. coli	E. polecki	E. nana
Trophozoites (size, nucleus, and movement)	15-20 μm; 1 nucleus; actively motile cytoplasmic protrusions, quickly finger shaped pseudopodium	8-10 μm; 1 nucleus; nonsuccessive	20-25 µm; 1 nucleus; slow movement, short and blunt pseudopodium	15-20 μm; 1 nucleus; motility resembles <i>E. coli</i>	7-9 µm; 1 nucleus, blunt and hyaline pseudopodium, slow movements
Cysts (size, nucleus)	12-15 μm; mature cyst has 4 nuclei, immature cyst has 1 or 2 nuclei	6-8 μm; mature cyst has 4 nuclei; immature cyst has 1 or 2 nuclei; 2 nucleated cysts very common	15-25 μm; mature cyst has 8 nuclei, rarely 16 or more nuclei	10-15 µm; 1 nucleus, very rarely binucleated or quadrinucleated	6-8 μm; 4 nuclei
Appearance of trophozoites	Stained trophozoites with fine, uniform granules of peripheral chromatin, and small central karyosome in nucleus; ingested RBC ( <i>E. dispar</i> and <i>E. moshkovskii</i> are similar to <i>E. histolytica</i> trophozoites, sometimes ingested RBCs)	Nuclear structure similar to <i>E</i> . <i>histolytica</i> ; cytoplasm finely granular; ingested bacteria	Nuclear with irregular cluster of peripheral chromatin; large, irregular, eccentric karyosome	Nucleus with minute central karyosome, with fine granules of peripheral chromatin, finely granular cytoplasm; ingested bacteria	Nucleus with large karyosome; no peripheral chromatin
Appearance of cysts	Typical nuclear structure is uniform size in having both karyosome and peripheral chromatin, chromatoidal bars with squared or rounded ends	Typical nuclear structure, chromatoidal bars with rounded or squared ends	Typical nuclear structure, sliver- shaped or irregular chromatoidals	Mononucleated; large central karyosome; chromatoid bars with pointed or angular ends, inclusion masses	Chromatin, 4 nuclei with large karyosomes and no peripheral chromatin
Pathogenicity	Only <i>E. histolytica</i> is pathogenic ( <i>E. dispar</i> and <i>E. moshkovskii</i> are nonpathogenic)	Nonpathogenic	Nonpathogenic	Nonpathogenic	Nonpathogenic

Table 1.2Morphologic features and pathogenicity of intestinal amoeba (Tanyuksel and Petri, 2003)

<sup>a</sup>*E. moshkovskii* is present in free-living protozoa.

Amoeba						
	Entamoeba histolytica, E. dispar and E. moshkovskii	Entamoeba hartmanni	Entamoeba coli	Entamoeba polecki*	Endolimax nana	lodamoeba butscħlii
Trophozoite		$\bigcirc$				0
Cyst						0

\*Rare, probably of animal origin



## 1.3.2 Intestinal Amoebiasis

Intestinal amoebiasis may present as amoebic colitis or amoebic dysentery. In cases suspected of intestinal amoebiasis, stool samples for three consecutive days are collected and sent for microscopy examination. Negative result from single samples does not rule out the possibility of amoebic infection. Polyvinyl alcohol (PVA) fixative or Schaudinn's fixative should be used during the stool specimen collection to preserve the fragile and rapid deteriorating trophozoites. However, direct wet mount on fresh stool samples are commonly performed in many laboratories to save cost and time, but the sensitivity is low. Therefore concentration technique such as zinc sulfate flotation technique and formalin ether sedimentation technique should be performed on 'negative' samples to decrease the possibility of false negative result. In many cases, live trophozoites could not be detected *via* concentration technique, as many will deteriorate during the process. Antigen detection tests like Techlab *E. histolytica* II and ProSpecT *Entamoeba histolytica* are more sensitive, but they are not routinely used in most of the developing counties due to the high cost. Figure 1.4 (A) shows the flowchart for clinical diagnosis of intestinal amoebiasis.

The clinical presentation of intestinal amoebiasis may be similar to enteric bacteria disease *e.g.* salmonellosis, shigellosis, enteropathogenic or enterohaemorrhagic *Escherichia coli*, as well as noninfectious inflammatory bowel disease and ischemic colitis. Besides, amoebic colitis can also be confused with the clinical presentation of Crohn's disease. It is important to rule out Crohn's disease prior to treatment with corticosteroid therapy as the treatment will worsen the condition of patient (Baron, 1996).

15



Figure 1.4Classical flow chart for diagnosis of amoebiasis

A. Intestinal amoebiasis; B. Extraintestinal amoebiasis

#### **1.3.3 Extraintestinal Amoebiasis**

The examination for extraintestinal amoebiasis is often started when patient experiences the symptoms of fever, nausea, hepatomegaly and tenderness in the right upper quadrant. Radiological imaging is performed to investigate the presence and size of the abscess. Depending on the physical condition of the patient and size of the abscess; the physician may aspirate the abscess for microscopy examination to check for the presence of live trophozoites, and also to rule out the possibility of liver necrosis. Culture of the abscess is also performed to rule out the possibility of pyogenic liver abscess that are caused by bacteria such as E. coli, Klebsiella spp., Staphylococcus spp. and Streptococcus spp. Live trophozoite is rarely found in the microscopy examination of aspirated pus as it is easily disintegrated and tendency of the trophozoites to line the peripheral margin of abscess, instead of the center part (Salles et al., 2003). The trials to harvest the trophozoites at the peripheral margin of abscess are ethically inappropriate, as this may harm the unnecessary normal liver tissue. Furthermore, for extraintestinal amoebiasis cases, the symptoms of intestinal amoebiasis may not be present, and trophozoites and cysts are rarely found in the stool samples. Therefore, many physicians often treat the patient based on the combination of clinical manifestations, serological test and radiological imaging. Figure 1.4 (B) shows the simple flowchart for diagnosis of extraintestinal amoebiasis (Baron, 1996).

### **1.4 TREATMENT FOR AMOEBIASIS**

Upon confirmation of diagnosis, physicians will prescribe drugs for treatment of patient. The drugs for treatment of intestinal and extraintestinal amoebiasis are shown in Tables 1.3 and 1.4. Each of the drugs has its side effects (Abdi *et al.*, 1995).

Physical condition of patient *e.g.* pregnancy will be taken into consideration prior to prescribing the drug. In asymptomatic carrier, once the *E. histolytica* species are confirmed, the patient should be treated to prevent spreading of the infective stage cysts. The drugs of choice included iodoquinol, paromomycin, and diloxanide furoate. The treatment for intestinal amoebiasis is similar to asymptomatic carrier. However, as the disease progress from mild intestinal amoebiasis to severe intestinal amoebiasis such as amoeboma or acute dysentery, the drug of choice will be tinidazole, metronidazole or paromomycin, in which the side effect will be greater.

The most common drug for treatment of extraintestinal amoebiasis is metronidazole. It is a highly lethal drug for anaerobic organism e.g. protozoa and bacteria. Besides, it also showed optimum pharmacokinetic features, in which it is easily absorbed in the intestine, has high bioavailability, wide systemic distribution including internal part of the abscess, and with a half-life of 14 hours. The dosage of the drugs that is effective for liver abscess is four times the minimum inhibitory concentration for the trophozoites. The drug can be administrated orally or by intravenous injection. The prescription for oral route is 750 mg of metronidazole, three times daily for 10 days for adult and 50 mg/kg/day for children. Whereby, 500 mg of metronidazole is introduced by intravenous infusion every 8 hours for 5 or 10 days. The common side effects of metronidazole include nausea, vomiting, headache and abdominal discomfort. Metronidazole should not be given to pregnant women during the first trimester of pregnancy and breastfeeding, as the drug is able to cross the placenta and able to enter breast milk. However, if amoebiasis is diagnosed in pregnant women, metronidazole is still the drug of choice but close follow up is needed (Salles et al., 2003; Upcroft and Upcroft, 2001; Zlobl, 2001).

Clinical	Drug of Choice	Dosage			
Classification	-	Adult	Pediatric		
Asymptomatic Carrier	Iodoquinol	650 mg <i>PO tid</i> x 20d	30-40 mg/kg/d (max 2g) <i>PO</i> in 3 doses x 20d		
	OR Paromomycin	25-35 mg/kg/d PO in 3 doses x 7d	25-35 mg/kg/d PO in 3 doses x 7d		
	OR Diloxanide furoate	500 mg <i>PO tid</i> x 10d	20 mg/kg/d <i>PO</i> in 3 doses x 10d		
Mild to Moderate Intestinal Amoebiasis	Metronidazole	500-750 mg <i>PO tid</i> x 7- 10d	35-50 mg/kg/d <i>PO</i> in 3 doses x 7-10d		
	OR Tinidazole	2 g once <i>PO</i> daily x 3d	$\geq$ 3yrs: 50 mg/kg/d (max 2g) once <i>PO</i> x 3d		
	(Either followed by Iodoquinol)	650 mg <i>PO tid</i> x 20d	30-40 mg/kg/d (max 2g) <i>PO</i> in 3 doses x 20d		
	OR Paromomycin	25-35 mg/kg/d PO in 3 doses x 7d	25-35 mg/kg/d PO in 3 doses x 7d		
Severe Intestinal and Extraintestinal	Metronidazole	750 mg <i>PO tid</i> x 7-10d	35-50 mg/kg/d <i>PO</i> in 3 doses x 7-10d		
Amoediasis	Tinidazole	2 g once <i>PO</i> daily x 5d	$\geq$ 3yrs: 50 mg/kg/d (max 2g) PO in 1 dose x 3d		
	(Either followed by Iodoquinol)	650 mg <i>PO tid</i> x 20d	30-40 mg/kg/d (max 2g) <i>PO</i> in 3 doses x 20d		
	Paromomycin	25-35 mg/kg/d PO in 3 doses x 7d	25-35 mg/kg/d PO in 3 doses x 7d		

# Table 1.3Drugs treatment for amoebiasis (The-Medical-Letter, 2010)

Note: *Tid* (thrice a day), d (day), *PO* (by mouth)

Drug	Mechanism	Adverse Effect	Comments
Metronidazole Or Tinidazole	Activated in anaerobic organisms by reduction of the 5-nitro group. Activated compound damages DNA	Metallic taste, nausea, vomiting, diarrhea. (Rarely result in sensory neuropathies, central nervous system toxicity with ataxia, vertigo, seizures and encephalopathy.)	Drug of choice for amoebic colitis and ALA.
Paromomycin	Aminoglycoside (inhibit protein synthesis)	Nausea, vomiting, cramps, diarrhea	Drug of choice for intestinal amoebiasis. It should be administrated to all individuals following completion of metronidazole therapy.
Iodoquinol	unknown	Headache, nausea, vomiting. Optic nerve damage and peripheral neuropathy reported in patient exceeding recommended dosage	Alternative to paromomycin
Diloxanide Furoate	unknown	Flatulence	Alternative to paromomycin

Table 1.4Mechanism and adverse effect of treatment drug for amoebiasis<br/>(Stanley, 2003)

#### 1.5 LABORATORY DIAGNOSIS OF AMOEBIASIS

Conventional diagnosis for amoebiasis is based on microscopy and isoenzyme analysis. With the advancement of technology, there were remarkable developments in molecular biology-based diagnostic tests for detection of *E. histolytica* including enzyme-linked immunosorbent assay (ELISA), indirect haemagglutination assay (IHA) and latex agglutination. With the advent of rapid diagnostic platforms, research on diagnostic kits that enhance point-of-care has also been initiated (Fotedar *et al.*, 2007; Petri and Singh, 1999).

### 1.5.1 Microscopy

Before molecular techniques were introduced, the diagnosis of amoebiasis is mainly based on clinical syndrome and microscopic examination of stool samples, which posed many problems. First, amoebiasis is often clinically under-diagnosed in developing areas, unless there is history of the patients returning from tropical area. Second, there is poor correlation between patients infected with amoeba and the development of symptomatic amoebiasis, as 90 % of infected individuals present as asymptomatic carriers (Barrett-Connor, 1971).

Besides, before the morphological similarity with the non-pathogenic strain, *E. dispar* was discovered, over-diagnosis and over-treatment were common. The third problem is the poor sensitivity of laboratory methods and low laboratory proficiency. Furthermore, stool examination require fresh samples as well as trained personnel to interpret the result (Mukhopadhyay *et al.*, 2000; Barrett-Connor, 1971). However, microscopic examination of stool samples for the protozoan morphology is still commonly practiced in many parasitology laboratories, especially in underdeveloped countries. It is mainly applied for diagnosis of intestinal amoebiasis but not extraintestinal amoebiasis, unless intestinal symptoms are present as well. It is difficult or even impossible to microscopically differentiate among all the human intestinal protozoa with similar morphological features, as shown in Figure 1.3 and Table 1.2. Thus, the sensitivity and specificity of microscopy examination for detection of *E. histolytica* in stool are low, due to the possibilities of misdiagnosis with other similar species *i.e. E. dispar* and *E. moshkovskii* (Liang *et al.*, 2009; Haque and Petri, 2006; Tanyuksel and Petri, 2003; WHO, 1997; Haque *et al.*, 1995).

The probable differential diagnosis based on microscopic identification of *E*. *histolytica* is the presence of trophozoites with red blood cells in dysenteric stool. However, the presence of trophozoites with ingested red blood cells is not frequent in all the intestinal cases. The possibilities of observing trophozoites is higher in loose stool which contained mucous, pus and trace amount of occult blood, whereas cysts could be observed in both formed and loose stools. The fresh stool samples must be processed fast as the trophozoites are rapidly disintegrated. If examination could not be performed immediately, the stools should be preserved in PVA or Schaudinn's fixative (Garcia and Shimizu, 1998).

The microscopy examination of stool samples can be performed directly or after staining. For direct stool examination, wet mount is commonly performed. The trophozoites and cysts can be easily identified, but the nucleus or central karyosome is difficult to see. With Lugol's iodine stain the internal features of the trophozoites and cyst are easily visible. Other stains *e.g.* methylene blue, Giemsa, Wright's and iodine-trichrome may be used for the staining as well, but Wheatley's trichrome

staining and modified iron haematoxylin permanent stain have been suggested for routine used (Fotedar *et al.*, 2007). In Wheatley's trichrome staining, trophozoites in stool samples are stained blue purple, while the background is stained light green. In addition, this stain also displays good chromatin lining and central karyosome of the nucleus. A recent study introduced an easy to perform Eosin Y staining method for trophozoites (*E. histolytica/E. dispar/E. moshkovskii*) in stool samples. The characteristic features of the amoeba are easily identified. The trophozoites are stained light red in stool samples, while the central karyosome and chromatin materials are stained distinctly dark in colour. This stain is suggested to be suitable for routine diagnosis as it is easy to perform and rapid. However, it is not for long term record keeping, as the stain fades away after one month (Tan *et al.*, 2010).

### 1.5.2 Biochemical Method: Culture and Isoenzyme Analysis

Culture of *E. histolytica* in artificial media *e.g.* Locke-egg medium, TYSGM-9, and TYI-S-33, followed by isoenzyme analysis has long been performed in many laboratories as the gold standard because it is able to differentiate between the pathogenic and non-pathogenic strains of *Entamoeba* spp. Four of the glycolytic enzymes namely hexokinase, phosphoglucomutase, glucose-6-phosphate isomerase (GPI), and malic enzyme have been applied in the isoenzyme analysis (Razmjou *et al.*, 2006). A total of 24 different zymodemes (isoenzyme analysis patterns) have been established, in which 21 zymodemes are from human isolates (9 patterns for *E. histolytica* and 12 patterns for *E. dispar*) and 3 are from experimentally cultured amoeba strains. Zymodeme is reliable in differentiation of *E. histolytica* and *E. dispar* due to the genetically different hexokinase enzymes between the species. The drawbacks of this method in laboratory diagnosis include being laboratory intensive

and time consuming. This method may need four to ten days to grow the trophozoites to a significant amount prior to starch-gel electrophoresis, and furthermore the culture may not always be successful (Haque and Petri, 2006; Ackers, 2002). Moreover, bacteria or other intestinal protist *e.g. Blastocystis hominis* may overgrow during the culture of trophozoites, and thereby affect the result of the zymodeme. The usage of this technique is now mainly for research purpose or epidemiological study (Fotedar *et al.*, 2007; Gatti *et al.*, 2002).

### **1.5.3** Antibody Detection

Serological method is commonly used in many laboratories for diagnosis of amoebiasis as the serum samples could be easily obtained and it is relatively less invasive. In endemic area, the detection of antibodies may be difficult due to the persistent high background antibody titer in the population. It is also usually unable to distinguish recent infection from past infection (Pillai *et al.*, 1999). Thus, serological result could only be as a supporting evidence for physician's diagnosis. In contrast, antibody detection method is effective for invasive amoebiasis cases in developed countries, as most of the individuals have no history of past infection.

In ALA, detection of anti-amoebic antibodies in serum samples was claimed to be ~100 % in sensitivity. Therefore, serological method is still a promising choice for diagnosis, together with other evidences from clinical manifestations and radiological imaging. The available antibody detection tests include ELISA, IHA, counterimmunoelectrophoresis (CIE), amoebic gel diffusion, complement fixation (CF), indirect fluorescent assay and latex agglutination. Nevertheless, the commonly used formats for diagnosis of amoebiasis are ELISA and IHA.